152 related articles for article (PubMed ID: 11069231)
1. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation.
Emery VC; Cope AV; Sabin CA; Burroughs AK; Rolles K; Lazzarotto T; Landini MP; Brojanac S; Wise J; Maine GT
J Infect Dis; 2000 Dec; 182(6):1610-5. PubMed ID: 11069231
[TBL] [Abstract][Full Text] [Related]
2. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG).
Hassan-Walker AF; Kidd IM; Sabin C; Sweny P; Griffiths PD; Emery VC
J Med Virol; 1999 Jun; 58(2):182-7. PubMed ID: 10335868
[TBL] [Abstract][Full Text] [Related]
3. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation.
Lao WC; Lee D; Burroughs AK; Lanzani G; Rolles K; Emery VC; Griffiths PD
J Med Virol; 1997 Mar; 51(3):152-8. PubMed ID: 9139077
[TBL] [Abstract][Full Text] [Related]
4. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
Pillet A; Mengelle C; Basse G; Ribes D; Kamar N; Muscari F; Lavayssière L; Suc B; Esposito L; Peron JM; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2335-8. PubMed ID: 16980083
[TBL] [Abstract][Full Text] [Related]
5. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation.
Cope AV; Sabin C; Burroughs A; Rolles K; Griffiths PD; Emery VC
J Infect Dis; 1997 Dec; 176(6):1484-90. PubMed ID: 9395358
[TBL] [Abstract][Full Text] [Related]
6. Monitoring human cytomegalovirus (HCMV) in HCMV-seropositive orthotopic liver-transplant recipients by means of quantitative real-time polymerase chain reaction.
Mengelle C; Abravanel-Legrand F; Kamar N; Alain S; Basse G; Pillet A; Lavayssière L; Suc B; Izopet J; Rostaing L
Exp Clin Transplant; 2006 Dec; 4(2):537-43. PubMed ID: 17238855
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease.
Gor D; Sabin C; Prentice HG; Vyas N; Man S; Griffiths PD; Emery VC
Bone Marrow Transplant; 1998 Mar; 21(6):597-605. PubMed ID: 9543064
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serology assays and polymerase chain reaction for the monitoring of active cytomegalovirus infection in renal transplant recipients.
Naumnik B; Małyszko J; Chyczewski L; Kovalchuk O; Małyszko J; Myśliwiec M
Transplant Proc; 2007 Nov; 39(9):2748-50. PubMed ID: 18021976
[TBL] [Abstract][Full Text] [Related]
9. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.
Westall GP; Michaelides A; Williams TJ; Snell GI; Kotsimbos TC
Transplantation; 2003 Jun; 75(12):2064-8. PubMed ID: 12829913
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and monitoring of human cytomegalovirus infection in bone marrow transplant recipients by quantitative competitive PCR.
Ziyaeyan M; Sabahi F; Alborzi A; Mahboudi F; Kazemnejad A; Ramzi M; Moravej A; Jaberi MM
Exp Clin Transplant; 2006 Jun; 4(1):470-4. PubMed ID: 16827646
[TBL] [Abstract][Full Text] [Related]
11. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation.
Cope AV; Sweny P; Sabin C; Rees L; Griffiths PD; Emery VC
J Med Virol; 1997 Jun; 52(2):200-5. PubMed ID: 9179769
[TBL] [Abstract][Full Text] [Related]
12. Qualitative detection of human cytomegalovirus DNA in the plasma of bone marrow transplant recipients: value as a predictor of disease progression.
Behzad-Behbahani A; Ehsanipour F; Alborzi A; Nourani H; Ramzi M; Rasoli M
Exp Clin Transplant; 2004 Jun; 2(1):196-200. PubMed ID: 15859928
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Lengerke C; Ljubicic T; Meisner C; Loeffler J; Sinzger C; Einsele H; Hebart H
Bone Marrow Transplant; 2006 Jul; 38(1):53-60. PubMed ID: 16788683
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients.
Kamar N; Mengelle C; Yahyaoui S; Sandres-Sauné K; Durand D; Izopet J; Rostaing L
J Clin Virol; 2005 May; 33(1):35-42. PubMed ID: 15797363
[TBL] [Abstract][Full Text] [Related]
15. HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
Härmä M; Loginov R; Piiparinen H; Halme L; Höckerstedt K; Lautenschlager I
Transplant Proc; 2005 Mar; 37(2):1230-2. PubMed ID: 15848678
[TBL] [Abstract][Full Text] [Related]
16. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of cytomegalovirus DNA by the polymerase chain reaction as a predictor of disease in solid organ transplantation.
Ghisetti V; Barbui A; Franchello A; Varetto S; Pittaluga F; Bobbio M; Salizzoni M; Marchiaro G
J Med Virol; 2004 Jun; 73(2):223-9. PubMed ID: 15122796
[TBL] [Abstract][Full Text] [Related]
18. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
Gerna G; Lilleri D
Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
[TBL] [Abstract][Full Text] [Related]
20. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
Emery VC; Sabin C; Feinberg JE; Grywacz M; Knight S; Griffiths PD
J Infect Dis; 1999 Sep; 180(3):695-701. PubMed ID: 10438356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
